Abstract
The precise inhibitory action of gabexate mesilate (GM) on the various pancreatic enzymes remains unclear. We designed this study to investigate the enzyme inhibitory action of GM in the serum and directly in the pancreatic juice. We observed 16 cases with postoperative pancreatic drainage. Patients were randomly assigned to one of two groups, to receive GM at a dose of 600 mg/24 hr (treated group: 8 patients) or a physiological solution (control group: 8 patients) by continuous intravenous infusion. In both groups pancreatic juice and serum were sampled three times: before infusion began (T0) and at 12 hr (T1) and 24 hr after infusion ended (T2). At the end of the study, seven patients received octreotide and the volume of pancreatic secretion was determined. No statistical difference was observed in serum amylase and phospholipase A2 activity in the treated and control groups. On the contrary, amylase and phospholipase A2 activity in the pancreatic juice diminished significantly only in the treated group, and in these patients a GM metabolite was also detectable in the pancreatic secretion. The volume of pancreatic secretion decreased only after infusion of octreotide. The enzyme inhibition in the pancreatic gland itself and the central role of inhibition of phospholipase A2 in the enzyme cascade responsible for activating other proteases, confirm the therapeutic use of GM in acute pancreatitis. An association of GM and octreotide during acute pancreatitis should be useful because of their different mechanisms.
Similar content being viewed by others
References
Kitagawa M, Naruse S, Ishiguro H, Hayakawa T: Pharmaceutical development for treating pancreatic diseases. Pancreas 16:427–431, 1998
Bassi C, Falconi M, Caldiron E, Salvia R, Sartori N, Butturini G, Contro C, Marcucci S, Casetti L, Pederzoli P: Assessment and treatment of severe pancreatitis. Protease inhibitor. Digestion 60 (Suppl 1):5–8, 1999
Dervenis C, Johnson CD, Bassi C, Bradley E, Imrie CW, McMahon MJ, Modlin I: Diagnosis, objective assessment of severity and management of acute pancreatitis. Int J Pancreatol 25:195–210, 1999
Trapnell JE, Rigby CC, Talbot CH, Duncan EH: A controlled trial of Trasylol in the treatment of acute pancreatitis. Br J Surg 61(3):177–182, 1974
Imrie CW, Benjamin IS, Ferguson JC, McKay AJ, Mackenzie I, O’Neill J, Blumgart LH: A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg 65:337–341, 1978
Harada H, Miyake H, Ochi K, Tanaka J, Kimura I: Clinical trial with a protease inhibitor Gabexate Mesilate in acute pancreatitis. Int J Pancreatol 9:75–79, 1991
Valderrama R, Pèrez-Mateo M, Navarro S, Vázquez N, Sanjosé L, Adrián MJ, Estruch J: Multicenter double-blind trial of gabexate-mesilate (FOY) in unselected patients with acute pancreatitis. Digestion 51:65–70, 1992
Buchler M, Malfertheiner P, Uhl W, Scholmerich J, Stockmann F, Adler G, Gaus W, Rolle K, Beger HG: Gabexate mesilate in human acute pancreatitis. Gastroenterology 104:1165–1170; 1993
Messori A, Rampazzo R, Scroccaro G, Olivato R, Bassi C, Falconi M, Pederzoli P, Martini N: Effectiveness of gabexate mesilate in acute pancreatitis. A metaanalysis. Dig Dis Sci 40(4):734–738, 1995
Pederzoli P, Cavallini G, Falconi M, Bassi C: Gabexate mesilate vs aprotinin in human acute pancreatitis. Int J Pancreatol 2:117–124, 1993
Cavallini G, Tittobello A, Frulloni L, Masci E, Mariani A, Di Francesco V: Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. N Engl J Med 335:919–923, 1996
Andriulli A, Leandro G, Clemente R, Festa V, Caruso N, Annese V, Lezzi C, Lichino E, Bruno F, Perri F: Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. Aliment Pharmacol Ther 12:237–245, 1998
Tanaka N, Tsuchiya, Ishii K: Comparative clinical study of FOY and Trasylol in acute pancreatitis. Adv Exp Med Biol 120B:367–368, 1979
Okegawa T, Fujita T, Yamamoto Y, Nakai H, Miyamoto K, Matsumoto K, Tani S: Effects of FOY on experimental acute pancreatitis. Curr Med 6:1–10, 1974
Caronna R, Diana L, Di Giavannandrea R, Campedelli P, Catinelli S, Nofroni I, Sibio S, Chirletti P: Gabexate mesilate (FOY) inhibition of amylase and phospholipase A2 activity in sow pancreatic juice. J Invest Surg 16:345–351, 2003
Hoffman GE, Schmidt D, Bastian B, Guder WG: Photometric determination of phospholipase A. J Clin Biochem 24 (11):871–875, 1986
Di Giovannandrea R, Diana L, Fiori M, Ferretti E, Foglietta G, Caronna R, Severini G: Determination of ethyl-p-hydroxybenzoate in sow pancreatic juice by reversed-phase high-performance liquid chromatography. J Chromatogr B 751:365–369, 2001
Keim K, Goke B: Pancreatic secretion in the rat influenced by the low molecular weight serine proteinase inhibitor gabexate mesilate. Eur J Clin Invest 16:519–525, 1986
Freise J, Melzer P, Schmidt FW, Horbach L: Gabexate mesilate in the treatment of acute pancreatitis. Results of a Hannover multicenter double-blind study with 50 patients. Z Gastroenterol 24(4):200–211, 1986
Freise J, Schmidt FW, Magerstedt P, Schmid K: Gabexate mesilate and camostate: new inhibitors of phospholipase A2 and their influence on the alpha-amylase activity in serum of patients with acute pancreatitis. Clin Biochem 18(4):224–229, 1985
Gronroos JM, Nevalainen TJ: Phospholipase A2 in acute pancreatitis: clinical value of phospholipase A2 measurements. Prog Surg 24:182–186, 1997
Arbibe L, Vial D, Touqui L: Phospholipase A2 and acute respiratory distress syndrome. Prog Surg 24:79–87, 1997
Uhl W, Buchler MW: Phospholipase A2 in surgical intensive care patients. Prog Surg 24:187–199, 1997
Royston D: Serine protease inhibition prevents both cellular and humoral responses to cardiopulmonary bypass. J Cardiovasc Pharmacol 27 (Suppl 1):S42–S49, 1996
Watanabe S: Acute pancreatitis:overview of medical aspects. Pancreas 16(3):307–311, 1998
Tamura Y, Hirado M, Okamura K, Minato Y, Fujii S: Synthetic inhibitors of trypsin, kallicrein, thrombin, C1r and C1esterase. Biochim Biophys Acta 484:417–422, 1977
Baxter JN, Jenkins SA, Day DW, Roberts NB, Cowell DC, Mackie CR, Shields R: Effects of somatostatin and a long-acting somatostatin analogue on the prevention and treatment of experimentally induced acute pancreatitis in the rat. Br J Surg 72:382–385, 1985
McKay CJ, Imrie CW, Baxter JN: Somatostatin and somatostatin analogues—Are they indicated in the management of acute pancreatitis? Gut 34:1622–1626, 1993
Lamberts SWJ, Van Der Lely A, De Herder WW, Hofland LJ: Octreotide. N Engl J Med 334(4):246–254, 1996
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Caronna, R., Diana, L., Nofroni, I. et al. Effects of Gabexate Mesilate (FOY) on Amylase and Phospholipase A2 in Human Serum and Pancreatic Juice. Dig Dis Sci 50, 868–873 (2005). https://doi.org/10.1007/s10620-005-2655-0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10620-005-2655-0